tag:blogger.com,1999:blog-7857054149675424609.post3568769389446916184..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: RNAi Drug Trounces Antisense Rival in Paris ATTR ShowdownDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-7857054149675424609.post-79178447889148161072018-01-05T22:28:35.384+01:002018-01-05T22:28:35.384+01:00https://twitter.com/zbiotech/status/94926555883863...https://twitter.com/zbiotech/status/949265558838632448<br /><br />zach <br />@zbiotech<br /><br />interesting LR doc survey re TTR (n=64) $ALNY $IONS - based on overall profile, 25% prefer patisiran, 23% inotersen, 52% are agnostic<br /><br />5:05 AM - 5 Jan 2018<br />Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-61716692503064934032017-11-23T12:08:12.296+00:002017-11-23T12:08:12.296+00:00Dirk,
I've not had time to look at the trial...Dirk, <br /><br />I've not had time to look at the trial results in detail, but one point stuck with me: ALNY APOLLO study population was sicker than the IONS one; do you think this could at least partially explain the different results? I also seem to remember that IONS saw more effect in the sicker sub-population... I'm not sure a small difference in Kd between siRNA and antisense (if PetraDhttps://www.blogger.com/profile/00801390021814714184noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-20992839118622751182017-11-18T22:24:58.613+00:002017-11-18T22:24:58.613+00:00Reply to question 1:
While Alnylam hasn’t reported...Reply to question 1:<br />While Alnylam hasn’t reported on looking at amyloid deposition from the APOLLO study, they had done so based on skin biopsies in the phase II OLE study. Based on that, I came away with the impression that there was some reduction in deposited amyloid, but that more robust TTR knockdown was need for a more forceful reduction. Amyloid folks seem to believe you need 90% Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-316647968342449292017-11-08T03:25:33.072+00:002017-11-08T03:25:33.072+00:00Two comments:
(1) it would make sense in your comm...Two comments:<br />(1) it would make sense in your commentary to at least make one perfunctory comment regarding comparing results across two different clinical trials. Any good scientist recognizes cross-trial comparisons are problematic at best.<br />(2) this was home court advantage for ALNY. I wouldn’t read too much into the crowd’s reactions.<br /><br />That said, I enjoy your blog. Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-50256073926409130542017-11-05T20:56:21.743+00:002017-11-05T20:56:21.743+00:00Since Alnylam is very focused in the hATTR-polyneu...Since Alnylam is very focused in the hATTR-polyneuropathy (hATTR-PN) therapeutic space, my expectation is they would be interested in pursuing additional lines of evidence that could demonstrate halting/clearance of amyloid deposition (e.g., via imaging methods) & potential for continued improvement in mNIS+7 change from baseline, beyond 18 months of treatment.<br /><br />Therefore, I have Anonymousnoreply@blogger.com